Key result
Neuropathological examination after neuroleptic malignant syndrome reveals no structural central nervous system damage.
Case Report (n=1)
Post-mortem neuropathological examination of a patient who suffered NMS showed normal findings, suggesting dopamine receptor blockade in NMS is not associated with structural CNS damage.
Answers are grounded in this paper and cite their sources.
Single case of normal post-NMS neuropathology warrants no practice change; leaves open structural CNS sequelae in larger cohorts.
Neuroleptic malignant syndrome (NMS) is a rare, life‐threatening complication of antipsychotic drug treatment. Its pathophysiology is controversial, and the same is true for the findings in post‐mortem studies on central nervous system pathology. In this report we present a patient who died two and a half months after suffering NMS. The findings in a thorough neuropathological examination were normal suggesting that the postulated dopamine receptor blockade in NMS is not associated with a structural central nervous system damage.
No takes yet. Share an insight, caveat, or question.
Koponen et al. (1993) conducted a case report in Neuroleptic malignant syndrome (n=1). Neuroleptic malignant syndrome was evaluated on Central nervous system pathology. Neuropathological examination of a patient who died 2.5 months after suffering neuroleptic malignant syndrome revealed normal findings, suggesting no structural central nervous system damage.
Synapse has enriched 10 related papers. Consider them for comparative context: